NK-One Therapeutics is a clinical-stage biotechnology company bridging the Survival Gap in oncology. By utilizing a precision molecular therapy to permanently silence the spinal neurons responsible for chronic refractory pain, we enable cancer patients to complete aggressive, life-saving treatments that are currently limited by debilitating physical suffering. Currently in Phase 1, high near term exit potential - complimentary cancer therapeutic.